Trial Profile

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Trametinib (Primary)
Indications Thyroid cancer
Focus Therapeutic Use
Acronyms I-FIRST; I-FIRST Study

Most Recent Events

14 Jul 2022 Status changed from not yet recruiting to recruiting.
23 May 2022 Planned initiation date changed from 30 Apr 2022 to 30 May 2022.
29 Mar 2022 Planned initiation date changed from 1 Mar 2022 to 30 Apr 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com